Allogene 2025 Q3 Earnings 37.5% Reduction in Net Loss to $-41.4M

Allogene Therapeutics (ALLO) reported fiscal 2025 Q3 earnings on Nov 6, 2025, , . , . , with key data catalysts expected in early 2026.

Revenue

The total revenue of Allogene remained stable at $0 in 2025 Q3 with no significant change from 2024 Q3.

Earnings/Net Income

. Meanwhile, , . The Company has sustained losses for 4 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. The EPS improvement reflects progress but underscores the need for continued operational efficiency to achieve profitability.

Price Action

, , .

Post-Earnings Price Action Review

. This backtest suggests that investors who follow this strategy have captured positive returns around earnings disclosures, highlighting the potential of ALLO’s financial performance to influence its stock price in a favorable manner.

CEO Commentary

, M.D., Ph.D., President, Chief Executive Officer, and Co-Founder of Allogene Therapeutics, emphasized the transformative potential of allogeneic CAR T therapy in enabling earlier, more precise treatment for oncology and autoimmune diseases. He highlighted the scalability of off-the-shelf cell therapy, driven by ex vivo manufacturing that enhances consistency, safety, and quality. Strategic priorities include advancing pivotal trials like ALPHA3 for cema-cel in large B-cell lymphoma and RESOLUTION for ALLO-329 in autoimmune disease, leveraging the to reduce lymphodepletion. The tone is optimistic, underscoring Allogene’s position at the forefront of a paradigm shift in cell therapy accessibility and broader care settings.

Guidance

, , cash equivalents, and investments for 2025. , . . The company excludes potential business development impacts from these estimates.

Additional News

, , . . A patent lawsuit involving licensor Cellectis in the U.S. remains a potential risk. Analysts maintain a “buy” rating, , reflecting optimism around upcoming data catalysts.